"In more than 25 years of my personal interaction with many major pharmaceutical companies, I have never dealt with another company that is so oriented to 'getting the job done.’ The cooperation of Reata staff has been spectacular, and the freedom from corporate red-tape has been very refreshing. We have truly worked in partnership to fully understand and exploit the medical potential of this very exciting new class of drugs."

-Michael Sporn,
Professor at Dartmouth Medical School, Author of over 20 “Nature” manuscripts, and inventor of Reata’s AIM compounds

In-Licensing

Reata is committed to partnering with leading academics to in-license and collaboratively develop promising technologies capable of delivering a therapeutic benefit to patients.

Reata has a successful track record in this area, having in-licensed promising technologies from leading institutions including:

	The University of Texas M. D. Anderson Cancer Center
	The University of Texas Southwestern Medical Center at Dallas
	Dartmouth College
	The National Cancer Institute

Reata offers a unique opportunity to our academic collaborators, allowing them to share financially in the company's overall success while ensuring that their project will be moved quickly and thoughtfully through the drug development process. Throughout the process, we actively collaborate with the technology inventors, taking advantage of their unique knowledge and expertise. Our collaborators consistently comment on how Reata's partnership approach is positively differentiated from their previous experiences in out-licensing technologies to large pharmaceutical firms.

Reata is interested in evaluating new technologies in the fields of cancer, neurological diseases, and inflammation. If you have a technology that you believe would fit with Reata, please Contact Us.